Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 528 000 new cases and 266 000 deaths in 2012 ([@bib15]). Cervical cancer screening with Papanicolaou cytology (Pap smear) has resulted in a major reduction in both the incidence of the disease and related mortality ([@bib28]; [@bib2]). However, screening coverage, estimated at 63% in developed countries and ranging from \>80% in Austria to \<50% in Ireland, remains often insufficient ([@bib19]). In the region of Tours, in France, where the study took place, screening coverage is estimated at 62.7% ([@bib13]). Common barriers to screening are accessibility to and acceptability of the pelvic examination needed for the cervical Pap smear ([@bib27]). France currently has no organised national cervical cancer screening programme.

Persistent infection with high-risk human papillomavirus (HR-HPV) is a cause of invasive cervical cancer ([@bib40]; [@bib29]). HPV-based tests have been recently proposed as an alternative to cervical cancer screening in women aged \>30 years and have been shown to be more sensitive than Pap smear in detecting cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN3 or cancer) ([@bib3]). These new screening tests have led to vaginal self-sampling modes with lavages, brushes or swabs. HPV tests performed on vaginal self-samples are accurate in detecting HPV cervical infection ([@bib34]). Moreover, tests with a dry swab are as accurate as those with a swab in liquid medium ([@bib25]).

Vaginal self-sampling has increased the participation in cervical cancer screening among unscreened women in various settings ([@bib6]; [@bib21]; [@bib37]; [@bib20]; [@bib36]; [@bib41]; [@bib38], [@bib39]; [@bib22]; [@bib30]; [@bib32]; [@bib12]; [@bib9]). However, most studies of participation involved self-sampling devices requiring a liquid transport medium, which may be impractical for collection and transport and costly. Other studies involved dry self-sampling devices, whose accuracy as compared with clinician-collected samples has not been evaluated or has been evaluated only with a limited number of women. Finally, few of these studies provided cost-effectiveness data.

In this randomised controlled trial, we assessed the efficacy of a strategy based on vaginal self-sampling with an in-home, mailed, validated, self-sampling kit with a dry swab to increase participation in cervical cancer screening among unscreened women. We also assessed the cost-effectiveness of such a strategy.

Materials and Methods
=====================

Design
------

We conducted a three-parallel-group randomised controlled trial. The study report follows the guidelines of the CONSORT statement extension for trials assessing non-pharmacological treatments and the template for intervention description and replication (TIDieR) checklist and guide ([@bib8]; [@bib26]).

Settings and participants
-------------------------

In 2010, in the absence of an organised national cervical cancer screening programme, the local Cancer Screening Department of the University Hospital of Tours established a regional cervical cancer screening programme. This department routinely collects health insurance reimbursement data and the major part (approximately 90%) of Pap smear results from pathologists\' files, which allows for identifying screened and unscreened women. Women identified as unscreened for ⩾3 years are invited by mail to visit their general practitioner (GP), gynaecologist or midwife to have a Pap smear. Nine months later, if they still have not had a Pap smear, they are sent a 'recall\' reminder letter.

The present study took place in the region managed by the Cancer Screening Department of the University Hospital of Tours, where about 160 000 women likely to be involved in a cervical cancer screening programme live. Eligible women were aged between 30 and 65 years and had not had a recent Pap smear despite an invitation 9 months previously. We excluded women who after the initial invitation declared that they (1) had a Pap smear in the past 3 years, (2) had a hysterectomy (including cervix), (3) had never had sexual intercourse or (4) had a cervical abnormality that was under exploration and/or treatment.

Interventions
-------------

We considered three groups defined as follows: (1) 'no intervention\' (2) 'recall\', women received a letter to visit a GP, gynaecologist or midwife to have a Pap smear; and (3) 'self-sampling\', women received a vaginal self-sampling kit.

For the 'self-sampling\' group, we tailored the intervention as follows ([Figure 1](#fig1){ref-type="fig"}). A working group of epidemiologists, gynaecologists, virologists and statisticians held discussion sessions. The group chose to use a swab rather than a brush or lavage as a self-sampling device because of its high acceptability, low price and good sampling performance ([@bib33]). In a previous study, we showed that HPV test results agreed among three formats: (1) a vaginal self-collected sample with a dry nylon flocked swab; (2) a vaginal self-collected sample with a nylon flocked swab in liquid medium; and (3) a clinician-collected cervical sample in liquid medium ([@bib25]). According to these findings, we selected the dry nylon flocked swab to avoid the use of a liquid medium.

The working group agreed on the content of the envelope sent to eligible women: (1) a letter inviting women to perform vaginal self-sampling, (2) a leaflet (designed in collaboration with a medical illustrator) explaining how to perform the vaginal self-sampling (Supplementary Information), (3) a nylon flocked swab in a non-breakable dry sterile tube (53080C, Copan, Brescia, Italy), (4) a resealable plastic bag, (5) an identification sheet, and (6) a prestamped, preaddressed envelope to return the self-sampling kit to a centralised laboratory (Virology Laboratory, Inter-Regional Health Institute, Tours, France) for HPV testing (see Laboratory testing below). If the HPV test result was uninterpretable, a new self-sampling kit was sent to the woman. If the second HPV test result was uninterpretable, women were advised by mail to have a Pap smear by health-care professional. Otherwise, if the test was negative for HR-HPV, the test result was mailed to the woman, and she was advised to have a Pap smear every 3 years. Finally, if the test was positive for HR-HPV, the test result was mailed to both the woman and her GP and the woman was advised to have a triage Pap smear as soon as possible (within 3 months). Three months after a positive HR-HPV test result, if the woman had not had a triage Pap smear, a reminder letter was sent. Three months later, if the woman had still not had a triage Pap smear, the woman was contacted by phone by the Cancer Screening Department staff. If the woman could not be contacted, a registered reminder letter with acknowledgement of receipt was sent, advising the woman to have a triage Pap smear as soon as possible.

For women with an abnormal screening or triage Pap smear test result, we collected follow-up results (HPV test, colposcopy, control Pap smear test, biopsy, etc.) according to Cancer Screening Department\'s usual procedures, in accordance with French Guidelines ([@bib17]): 4--9 months (depending of the Pap smear test result) after the abnormal Pap smear test result, a letter was sent (with prestamped, preaddressed return envelope) to the GP and/or the gynaecologist of the woman to collect follow-up results or to remind the need for follow-up if it had not been achieved. If no result could be collected, a letter was sent to the woman 1 year after the abnormal Pap smear test result to collect follow-up results or to remind the need for follow-up if it had not been achieved.

Randomisation sequence generation, allocation concealment, implementation
-------------------------------------------------------------------------

Among eligible women, 6000 were randomly selected (see sample size section): 3000 who were 30--49 years old, and 3000 who were 50--65 years old. Then, within the two age strata, women were randomly assigned in equal proportions (1 : 1 : 1) to one of the three groups, all at once. Both the random sampling and the randomisation were handled by an independent computer programmer who is in charge of the screening programme management software routinely used in the Cancer Screening Department (Zeus, OsiSanté, Thury Harcourt, France) and who was not further involved in the study. The allocation method was concealed to the study coordinator.

Ethics approval and blinding
----------------------------

The study protocol was approved by the local ethics committee who considered the study as a study on women\'s behaviour in response to a screening offer and therefore waived the requirement for informed consent. In both the 'recall\' and 'self-sampling\' groups, the letter sent indicated that participation was part of a research programme about screening, but women were not aware that there were included in a randomised trial. Finally, women in the 'no intervention\' group received no information and therefore were unaware of the present study. In parallel, before randomisation, all GPs, gynaecologists and midwives working in the region where the study took place were informed by mail of the study\'s objectives. At the end of the study (April 2013), all included women received comprehensive information about the study hypothesis, study results and cervical cancer screening guidelines.

Laboratory testing
------------------

Pap smears were evaluated in cytology laboratories according to usual practices. PCR-based HPV tests were performed by well-trained virologists in a centralised laboratory (Virology Laboratory). Samples were first eluted in 3-ml buffer solution of phosphate-buffered saline. Then, samples were tested for HPV following the routine procedure previously described ([@bib25]) with HPV type-specific oligonucleotide probes bound to nitrocellulose strips (INNO-LiPA HPV Genotyping Extra, Innogenetics, Ghent, Belgium) according to the manufacturer\'s protocol ([@bib16]; [@bib31]). The assay could identify 28 HPV types, including 15 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82), 3 probable high-risk HPV types (HR-HPV; 26, 53, 66), 7 low-risk HPV types (LR-HPV; 6, 11, 40, 43, 44, 54, 70) and 3 additional types with unknown risk (69, 71, 74). The assay included a control line. A negative result for the control line indicated inadequate specimen collection or the presence of inhibitors in the DNA extract. In this case, the test result was considered uninterpretable.

HPV results were classified as positive for HR-HPV when at least one HR-HPV or probable HR-HPV type was detected and negative when no HPV or other HPV type was detected (low-risk HPV, additional types, untypable).

Outcome measurement
-------------------

Outcomes were assessed by the Cancer Screening Department from routinely collected data and HPV test results. The primary outcome was participation in complete cervical cancer screening within 9 months after randomisation. The secondary outcome was participation in complete screening within 12 months.

In the 'no intervention\' and 'recall\' groups, participation in complete screening was defined as having a Pap smear. In the 'self-sampling\' group, participation in complete screening was defined as having a Pap smear or performing the self-sampling, eventually completed by a triage Pap smear performed by health-care professional in case of positive test results. Indeed, in case of negative results, the participation was considered complete, and, in case of positive results, the participation was considered complete with a triage Pap smear performed by health-care professional as recommended ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

Finally, cytology (Pap smear) and histology (biopsy) results were extracted from routinely collected data from the Cancer Screening Department database. Pap smear results were classified by the 2001 Bethesda system ([@bib35]). Women who performed at least one follow-up test (control Pap smear test, HPV test, colposcopy) consistent with French Guidelines ([@bib17]) were considered to have began a follow-up procedure; those who performed a complete follow-up procedure consistent with the French Guidelines were considered to have a full follow-up. Histology results were classified as normal, CIN1, CIN2, CIN3 or cancer.

Sample size determination
-------------------------

From comparable published data ([@bib6]; [@bib36]) and based on knowledge of the local situation in the screening programme, we assumed a 30% participation rate in the 'no intervention\' group. We hypothesised a 5% increase in participation in the 'recall\' group, and a further 5% increase in the 'self-sampling\' group. Considering that pairwise comparisons would be performed, we considered a two-sided alpha level of 0.0167 and a power of 80%, for 1953 women needed in each group. Finally, 6000 women were included.

Statistical analysis
--------------------

Analyses followed the principle of intent-to-screen. Participation rates were reported with their 95% confidence intervals (95% CIs). Odds ratios (ORs) were estimated by logistic models. Subgroup analyses were performed considering interaction terms between age and intervention groups. The 'no intervention\' group was considered as the reference for comparisons. Data were analysed by the use of SAS v9.2 (SAS Inc., Cary, NC, USA).

Medico-economic evaluation
--------------------------

A cost-effectiveness analysis was performed according to the guidelines of the French National Authority for Health ([@bib18]). The societal point of view was adopted to consider costs supported by health insurance, the Cancer Screening Department and women. Only direct costs were taken into account (Table 4).

A cost per screened woman was calculated for each group. Interventions were ranked in terms of costs from the cheapest to the most expensive. If an intervention was more expensive and less effective than the previous one, then it was said to be strongly dominated and was excluded from further analysis. Incremental cost-effectiveness ratios (ICERs) per extra screened woman were calculated for each intervention by dividing the between-strategy cost difference by the between-strategy number of screened women. ICERs for each intervention were compared with the next most-expensive, non-dominated option. If the ICER for an intervention was higher than that for the next most-effective intervention, it was ruled out by extended dominance. ICERs were then recalculated for the remaining interventions. A sensitivity analysis was conducted to account for the uncertainty of efficacy results and cost trends.

Results
=======

Participants
------------

Between November 2010 and April 2011, 38 505 women in the study area were identified as unscreened for cervical cancer. They were invited to visit their GPs, gynaecologist or midwife to have a Pap smear: 7811 had a Pap smear and 4464 reported exclusion criteria. On March 2012, among the 26 230 remaining women (median age 51.1 years, range 30.0--65.0), 6000 women (3000, 30--49 years; and 3000, 50--65 years) were randomly selected and randomised to one of the three groups. Because of duplicate selection, 2 women were further excluded, which led to a final sample of 5998 women.

Study conduct
-------------

Because of address errors, recall letters could not be delivered to 156 women (7.8%), nor 164 (8.2%) self-sampling kits. In the 'self-sampling\' group, four women had an uninterpretable HPV test result; two performed a second self-sampling, but one test result was again uninterpretable. The two other women did not perform a second self-sampling.

Participation in complete cervical cancer screening
---------------------------------------------------

At 9 months after randomisation, the participation in complete cervical cancer screening was significantly higher for the 'self-sampling\' than for the 'no intervention\' group (22.5% *vs* 9.9% OR 2.64, 95% CI (2.21; 3.17) and the 'recall\' group (11.7%, OR 2.20, 95% CI (1.85; 2.62), with no difference between the 'recall\' and 'no intervention\' groups (OR 1.20, 95% CI (0.98 ; 1.47)). In the 'self-sampling\' group, of the 320 women (16.0%, 95% CI (14.4; 17.7)) who returned a self-sample, 313 (15.7%, 95% CI (14.1; 17.3)) were considered as screened by self-sampling (see 'Test results and follow-up\' section), whereas 137 women (6.9%, 95% CI (5.8; 8.1)) directly performed a screening Pap smear ([Table 1](#tbl1){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}).

For the two age subgroups, results were qualitatively the same, except for women aged 50--65 years, the participation rate was higher for the 'recall\' than for the 'no intervention\' group.

Results were stable at 12 months after randomisation ([Table 2](#tbl2){ref-type="table"}). Between months 9 and 12 after randomisation, 3 women performed self-sampling (negative for HR-HPV) and 50 had a Pap smear in the 'no intervention\' group, 43 in the 'recall\' group and 35 in the 'self-sampling\' group.

Test results and follow-up
--------------------------

In the 'self-sampling\' group, 320 women performed self-sampling within 9 months and 317 test results were interpretable, with 44 samples (13.9%, 95% CI (10.3;18.2)) positive for HR-HPV ([Figure 2](#fig2){ref-type="fig"}); 40 of these women had the recommended triage Pap smear (90.9%, 95% CI (78.3; 97.5)).

Among women who participated in complete screening at 12 months after randomisation, a Pap smear test result was available for 653 out of 736 (88.7%): 218 out of 248 (87.9%) in the 'no intervention\' group, 250 out of 276 (90.6%) in the 'recall\' group, and 185 out of 212 (87.3%) in the 'self-sampling\' group. For the remaining women, only the health insurance reimbursement date of the Pap smear test was known. Among 653 Pap smear test results, 32 (4.9%) were abnormal with 26 on a screening Pap smear test and 6 on a triage Pap smear test after positive HR-HPV result on the vaginal self-sampling; 8 out of 218 (3.7%) in the 'no intervention\' group, 11 out of 250 (4.4%) in the 'recall\' group and 13 out of 185 (7.0%) in the 'self-sampling\' group, (7 out of 150 among women who performed a screening Pap smear and 6 out of 35 among triage Pap smear) ([Table 3](#tbl3){ref-type="table"}).

Among 32 women with abnormal screening or triage Pap smear test result, 27 (84.4%, 95% CI (67.2; 94.7)) began a follow-up procedure (i.e., had at least one follow-up test) of which 14 had a full follow-up (complete and consistent with guidelines): 7 out of 8 began a follow-up (2 full follow-ups) in the 'no intervention\' group, 9 out of 11 began a follow-up (5 full follow-ups) in the 'recall\' group, and 11 out of 13 began a follow-up (7 full follow-ups) in the 'self-sampling\' group. In this latter group, 5 out of 7 began a follow-up (3 full follow-ups) in women who directly performed a screening Pap smear, and 6 out of 6 began a follow-up (4 full follow-ups) in women who had an abnormal triage Pap smear test result after a positive HR-HPV test result on a self-sample. Among 26 women with abnormal screening Pap smear test result (excluding the 6 women with an abnormal triage Pap smear test result), 21 (80.8%, 95% CI (60.6; 93.4)) began a follow-up procedure of which 10 had a full follow-up.

Finally, among women who participated in complete screening at 12 months after randomisation, 7 had CIN2 grade cancer or worse: 1 CIN3 in the 'no intervention\' group and 1 CIN3 in the 'recall\' group; and 3 CIN3 in the 'self-sampling\' group among HR-HPV-positive women and 2 CIN2 in the 'self-sampling\' group among women who had a Pap smear. The CIN2+ detection rate among included women was 0.50‰ (95% CI (0.01; 2.78)) in the 'no intervention\' and 'recall\' groups and 2.5‰ (95% CI (0.81 ; 5.83)) in the 'self-sampling\' group.

Cost-effectiveness analysis
---------------------------

The total cost was higher for the 'self-sampling\' than for the 'recall\' group (26 855.95€ *vs* 13 651.27€) and the 'no intervention\' group (10 929.62€). No strategy strongly dominated (more expensive and less effective) ([Table 4](#tbl4){ref-type="table"}). The ICER per extra screened woman was 77.8€ in the 'Recall\' group (ruled out by extended dominance) and 63.2€ in the 'self-sampling\' group relative to the 'no intervention\' group. Sensitivity analysis revealed that ICERs were related to participation rates, screening test costs (Pap smear analysis and HPV test), medical consultation extra fees, postal fees and self-sampling device cost.

Discussion
==========

In a large sample of 5998 women, we showed that an in-home, mailed, vaginal self-sampling kit with a dry swab increased participation in a cervical cancer screening programme among previous non-attendees. These results apply to women both 30--49 and 50--65 years old. Recall letters were not more effective than no intervention, particularly among younger women. Among women with a positive HR-HPV test result, 90.9% had the recommended Pap smear by a health-care professional. The cost-effectiveness analysis showed that the additional costs of the self-sampling strategy were offset by the substantial increase in participation, if using an inexpensive self-sampling device.

Several studies assessed the effect on screening participation of in-home, mailed, vaginal self-sampling kits as compared with recall letters ([Table 5](#tbl5){ref-type="table"}; [@bib6]; [@bib21]; [@bib37]; [@bib20]; [@bib36]; [@bib41]; [@bib38], [@bib39]; [@bib22]; [@bib32]; [@bib12]; [@bib9]). Despite the large heterogeneity in participation rates among studies, the self-sampling strategy increased participation in cervical cancer screening, whatever the study, that is, whatever the setting and the device (liquid transport or dry). Therefore, our findings agree with previously reported results. We further showed that a recall letter had no effect on participation as compared with no intervention. Extrapolating the findings of our study to the whole cervical cancer screening programme in the region of Tours where the study took place, an in-home mailed vaginal self-sampling strategy could increase the total estimated screening coverage from 62.7% to 67.3%. Moreover, to our knowledge, our study was the first to provide cost-effectiveness data for vaginal self-sampling increasing participation among unscreened women with a validated dry self-sampling device and a PCR-based HPV test.

From a practical viewpoint, neither the self-sampling device (brush, swab or lavage) ([@bib4]) nor the transport method (liquid or dry) ([@bib10]; [@bib5]; [@bib14]; [@bib11]; [@bib25]) seemed to significantly affect the sensitivity and specificity of the self-sampling test and the efficacy in increasing participation. Therefore, when defining a screening programme, logistical and cost issues should be the major criteria to select a self-sampling device and transport method for a screening programme ([@bib24]), and dry devices could meet those criteria.

In a recent meta-analysis of the accuracy of HPV testing with clinician- *vs* self-collected samples. [@bib4] suggested that, given their high sensitivity, PCR-based HPV testing is preferred to hybrid capture methods for self-samples. For self-sampling, use of a test with a high analytic sensitivity seems to be needed to ensure similar accuracy between clinician- and self-collected samples, probably because of the lower viral load in the vagina than the cervix ([@bib7]; [@bib24]; [@bib42]).

From a medico-economic viewpoint, our data show that despite a higher total cost of self-sampling, the strategy could be cost-effective as compared with a recall letter when considering the cost per extra screened woman. This finding was linked in particular to the large difference in participation with the two strategies and the low cost of the self-sampling device we used. Further exploration is needed of the cost per quality-adjusted life years of a self-sampling strategy based on an inexpensive device; such data could be obtained by using our data in an existing medico-economic model ([@bib23]).

In conclusion, policy makers could consider vaginal self-sampling as an alternative to recall letters to increase participation in organised cervical cancer screening programmes. However, careful attention should be paid to defining the women to target, the device to use and to each logistical detail to optimise participation, efficacy and cost-effectiveness. Therefore, a well-organised cervical cancer screening programme ([@bib1]) should be an essential precondition to implement an effective and efficient self-sampling strategy.
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![**Procedure for the 'self-sampling\' group.** Abbreviation: HPV, human papillomavirus.](bjc2014510f1){#fig1}

![**Study flow chart and results.** Abbreviations: HR-HPV+, positive for high-risk HPV and/or probable high-risk HPV; HR-HPV−, negative for high-risk HPV and probable high-risk HPV; UI, uninterpretable HPV test result. 95% confidence intervals are presented in brackets.](bjc2014510f2){#fig2}

###### Participation in complete cervical cancer screening within 9 months after randomisation, by intervention and age groups

                                                                                    **Participation**                                                          
  ---------------------------------------------- ---------------------------------- ------------------- ---------------------------------------- ------------- -------------------
                                                 No intervention group (*n*=1999)   198 (9.9%)                            ---                    198 (9.9%)           1.00
  Total                                          Recall group (*n*=2000)            233 (11.7%)                           ---                    233 (11.7%)    1.20 (0.98; 1.47)
                                                 Self-sampling group (*n*=1999)     137 (6.9%)           313 (15.7%)[a](#t1-fn2){ref-type="fn"}  450 (22.5%)    2.64 (2.21; 3.17)
  Subgroup analysis[b](#t1-fn3){ref-type="fn"}                                                                                                                 
                                                 No intervention group (*n*=1000)   104 (10.4%)                           ---                    104 (10.4%)          1.00
  Women aged 30--49 years                        Recall group (*n*=1000)            94 (9.4%)                             ---                    94 (9.4%)      0.89 (0.67; 1.20)
                                                 Self-sampling group (*n*=999)      73 (7.3%)                         147 (14.7%)                220 (22.0%)    2.43 (1.89; 3.13)
                                                 No intervention group (*n*=999)    94 (9.4%)                             ---                    94 (9.4%)            1.00
  Women aged 50--65 years                        Recall group (*n*=1000)            139 (13.9%)                           ---                    139 (13.9%)    1.55 (1.18; 2.05)
                                                 Self-sampling group (*n*=1000)     64 (6.4%)                         166 (16.6%)                230 (23.0%)    2.88 (2.22; 3.72)

Abbreviation: CI=confidence interval.

Within 9 months after randomisation, 320 women performed vaginal self-sampling, but only 313 were considered as having participated in complete screening action because 4 did not have the recommended Pap smear and 3 had an uninterpretable HPV test result.

Interaction test, *P*=0.0193.

###### Participation in a complete cervical cancer screening within 12 months after randomisation, by intervention and age groups

                                                                                    **Participation**                                                          
  ---------------------------------------------- ---------------------------------- ------------------- ---------------------------------------- ------------- -------------------
                                                 No intervention group (*n*=1999)   248 (12.4%)                           ---                    248 (12.4%)          1.00
  Total                                          Recall group (*n*=2000)            276 (13.8%)                           ---                    276 (13.8%)    1.13 (0.94; 1.36)
                                                 Self-sampling group (*n*=1999)     172 (8.6%)           316 (15.8%)[a](#t2-fn2){ref-type="fn"}  488 (24.4%)    2.28 (1.93; 2.70)
  Subgroup analysis[b](#t2-fn3){ref-type="fn"}                                                                                                                 
                                                 No intervention group (*n*=1000)   137 (13.7%)                           ---                    137 (13.7%)          1.00
  Women aged 30--49 years                        Recall group (*n*=1000)            112 (11.2%)                           ---                    112 (11.2%)    0.79 (0.61; 1.04)
                                                 Self-sampling group (*n*=999)      92 (9.2%)                         148 (14.8%)                240 (24.0%)    1.99 (1.58; 2.51)
                                                 No intervention group (*n*=999)    111 (11.1%)                           ---                    111 (11.1%)          1.00
  Women aged 50--65 years                        Recall group (*n*=1000)            164 (16.4%)                           ---                    164 (16.4%)    1.57 (1.21; 2.03)
                                                 Self-sampling group (*n*=1000)     80 (8.0%)                         168 (16.8%)                248 (24.8%)    2.64 (2.07; 3.37)

Abbreviation: CI=confidence interval.

Within 12 months after randomisation, 324 women performed vaginal self-sampling, but only 316 were considered as having participated in complete cervical cancer screening because 4 did not have the recommended Pap smear and 3 had an uninterpretable HPV test result.

Interaction test, *P*=0.0014.

###### Pap smear results by intervention group and the type of participation among women who participated in complete cervical cancer screening within 12 months after randomisation

                                              **Intervention group**                                            
  ------------------------------------------- ------------------------ ------------- ------------- ------------ -------------
  Unknown result[b](#t3-fn3){ref-type="fn"}   30 (12.1%)               26 (9.4%)     22 (12.8%)    5 (12.5%)    27 (12.7%)
  Known result[c](#t3-fn4){ref-type="fn"}     218 (87.9%)              250 (90.6%)   150 (87.2%)   35 (87.5%)   185 (87.3%)
   Normal                                     210 (84.7%)              239 (86.6%)   143 (83.1%)   29 (72.5%)   172 (81.1%)
   Abnormal                                   8 (3.2%)                 11 (4.0%)     7 (4.1%)      6 (15.0%)    13 (6.1%)
    ASC-US                                    3 (1.2%)                 8 (2.9%)      3 (1.7%)      2 (5.0%)     5 (2.4%)
    ASC-H                                     1 (0.4%)                 ---           1 (0.6%)      ---          1 (0.5%)
    LSIL                                      3 (1.2%)                 2 (0.7%)      1 (0.6%)      1 (2.5%)     2(0.9%)
    HSIL                                      1 (0.4%)                 1 (0.4%)      1 (0.6%)      3 (7.5%)     4 (1.9%)
    AGC                                       ---                      ---           1 (0.6%)      ---          1 (0.5%)

Abbreviations: AGC=atypical glandular cells; ASC-H=atypical squamous cells, cannot rule out high-grade lesion; ASC-US=atypical squamous cells of undetermined significance; HSIL=high-grade squamous intraepithelial lesions; LSIL=low-grade squamous intraepithelial lesions. Data are number of samples.

Among the 44 women with a positive HR-HPV test result on the vaginal self-sampling, 4 did not have the recommended triage Pap smear.

The date for the Pap smear was known but not the cytology result.

According to the 2001 Bethesda system.

###### Resources required per screened women by intervention group

                                                                                                                          **No intervention (*****n*****=1999)**   **Recall (*****n*****=2000)**   **Self-sampling (*****n*****=1999)**                                                  
  ------------------------------------------------------------------------------------------------- -------------------- ---------------------------------------- ------------------------------- -------------------------------------- ----------------------------------- ----------- -----------------------------------
                                                                                                    **Unit costs (€)**                  **Units**                          **Cost (€)**                         **Units**                           **Cost (€)**              **Units**             **Cost (€)**
  Identification of screened and unscreened women[a](#t4-fn2){ref-type="fn"}                                                                                                  398.00                                                                   398.00                                          398.00
  **Intervention**                                                                                                                                                                                                                                                                       
  Recall letter[b](#t4-fn3){ref-type="fn"}                                                          0.43                                                                                                           2000                                860.00                                              
  Self-sampling kit[c](#t4-fn4){ref-type="fn"}                                                      2.30                                                                                                                                                                        1999                   4597.70
  **Screening**                                                                                                                                                                                                                                                                          
  Pap smear[d](#t4-fn5){ref-type="fn"}                                                              53.19                                  198                               10 531.62                             233                                12 393.27                  137                   7287.03
  Self-sampling return and HPV test[e](#t4-fn6){ref-type="fn"}                                      38.39                                                                                                                                                                        320                  12 284.80
  **Uninterpretable HPV test result**                                                                                                                                                                                                                                                    
  Self-sampling kit[c](#t4-fn4){ref-type="fn"}                                                      2.30                                                                                                                                                                          4                     9.20
  Self-sampling return and HPV test[e](#t4-fn6){ref-type="fn"}                                      38.39                                                                                                                                                                         2                     76.78
  **Follow-up for HR-HPV+**                                                                                                                                                                                                                                                              
  Pap smear[d](#t4-fn5){ref-type="fn"}                                                              53.19                                                                                                                                                                        40                    2127.60
  Reminder letter within 3 months[f](#t4-fn7){ref-type="fn"}                                        0.62                                                                                                                                                                         32                     19.84
  Reminder phone call within 6 months[g](#t4-fn8){ref-type="fn"}                                    5.00                                                                                                                                                                         11                     55.00
  Total cost                                                                                                                                                                 10 929.62                                                                13 651.27                                       26 855.95
  No. of screened women[h](#t4-fn9){ref-type="fn"}                                                                                         198                                                                     233                                                           450                       
  Cost per screened woman (95% CI)[i](#t4-fn10){ref-type="fn"}                                                                                                          55.2€ (54.9; 55.4)                                                       58.6€ (58.1; 59.2)                              59.7€ (58.6; 62.2)
  ICER per extra screened woman[j](#t4-fn11){ref-type="fn"}                                                                                                                                                                               77.8€[k](#t4-fn12){ref-type="fn"}                             63.2€
  **Sensitivity analysis (ICER per extra screened woman**[j](#t4-fn11){ref-type="fn"})                                                                                                                                                                                                   
  Efficacy parameters                                                                                                                                                                                                                                                                                      
   Participation rate (worst assumption  for the self-sampling group)[l](#t4-fn13){ref-type="fn"}                                                                                                                                                       62.7€                             63.1€[k](#t4-fn12){ref-type="fn"}
  Screening costs                                                                                                                                                                                                                                                                                          
   No extra fees for medical consultation                                                                                                                                                                                                 68.8€[k](#t4-fn12){ref-type="fn"}                             63.9€
   HPV test=cytology analysis=25€                                                                                                                                                                                                         87.4€[k](#t4-fn12){ref-type="fn"}                             47.8€
   HPV test=25€                                                                                                                                                                                                                           77.8€[k](#t4-fn12){ref-type="fn"}                             48.6€
  Intervention costs                                                                                                                                                                                                                                                                                       
   Postal fees +20%                                                                                                                                                                                                                       82.9€[k](#t4-fn12){ref-type="fn"}                             66.9€
   Postal fees −20%                                                                                                                                                                                                                       77.2€[k](#t4-fn12){ref-type="fn"}                             59.6€
   Self-sampling kit 5.00€ (*vs* 2.30€)                                                                                                                                                                                                                 77.8€                             84.6€[k](#t4-fn12){ref-type="fn"}

Abbreviations: CI=confidence interval; HR-HPV=high-risk human papillomavirus; ICER=incremental cost-effectiveness ratio.

Cancer Screening Department staff time and equipment.

Envelope, letterhead paper, printing and postal fee.

Envelope, letterhead paper, printing, postal fee, self-sampling device, leaflet, resealable zipper bag, identification sheet and return envelope.

Consultation (general practitioner, midwife or gynaecologist) including potential extra fees, cytology analysis and Cancer Screening Department staff time for result import.

Postal fee for sampling return, HPV test analysis and sending the result.

Envelope, letterhead paper, printing and postal fee.

Cancer Screening Department staff time.

Participation in complete cervical cancer screening within 9 months.

Confidence intervals were computed with a Bootstrap method.

The 'No intervention\' group was the reference strategy.

Ruled out strategy by extended dominance.

Worst assumption for the self-sampling group: participation rate lower limit of the 95% CI for the 'no intervention group (8.6%) and for the self-sampling group (20.7%) and upper limit for the recall group (13.1%).

###### Randomised controlled trials comparing the efficacy of a self-sampling kit and recall letters in participation in cervical cancer screening

                                                                                                                                                  **Participation**           
  ----------------------------------- ---------------------- -------------------- ------------------------------------ ---------------- --------- ------------------- ------- ------------
  [@bib6]                             Netherlands (2830)     Brush                Liquid                               **PCR-based**     **Yes**  34.2%               17.6%   \<0.001
  [@bib21]                            Netherlands (28 073)   Lavage               Liquid                               Hybrid capture      No     27.5%               16.6%   \<0.001
  [@bib20]                            Italy (2480)           Lavage               Liquid                               Hybrid capture      No     19.6%               13.9%   *0.007*
  [@bib36]                            Great Britain (3000)   Cotton swab          Liquid                               Hybrid capture      No     10.2%               4.5%    \<0.0001
  [@bib38]                            Finland (4160)         Lavage               Liquid                               Hybrid capture      No     29.8%               26.2%   *0.021*
  [@bib41]                            Sweden (4060)          Plastic wand         **Dry**[b](#t5-fn3){ref-type="fn"}   Hybrid capture      No     39.0%               9.0%    \<0.001
  [@bib39]                            Finland (8699)         Lavage               Liquid                               Hybrid capture      No     31.5%               25.9%   *\<0.0001*
  [@bib22]                            Netherland (26 409)    Brush                Liquid                               Hybrid capture      No     30.8%               6.5%    \<0.001
  [@bib37]                            France (9334)          Nylon flocked swab   Liquid                               **PCR-based**       No     25.1%               7.3%    \<0.001
  [@bib12]                            Sweden (1500)          Cotton swab          **Dry**[c](#t5-fn4){ref-type="fn"}   **PCR-based**       No     14.7%               4.2%    \<0.0001
  [@bib32]                            France (18 730)        Nylon flocked swab   Liquid                               **PCR-based**       No     18.3%               2.0%    \<0.001
  [@bib9]                             Sweden (8800)          Plastic wand         **Dry**[b](#t5-fn3){ref-type="fn"}   Hybrid capture    **Yes**  24.5%               10.6%   *\<0.0001*
  Haguenoer *et al* (present study)   France (6000)          Nylon flocked swab   **Dry**[d](#t5-fn5){ref-type="fn"}   **PCR-based**     **Yes**  22.5%               11.7%   \<0.0001

Abbreviations: HPV=human papillomavirus.

We calculated *P*-values when they were not available in the original publication (italics in the table).

The accuracy of this self-sampling and transport method had not been compared with a clinician-collected sample to our knowledge.

The accuracy of this self-sampling and transport method had been compared with a clinician-collected sample for 121 women ([@bib11]).

The accuracy of this self-sampling and transport method was compared with a clinician-collected sample and with a self-collected sample in liquid transport medium for 732 women ([@bib25]).
